Generic Name and Formulations:
Diethylpropion HCl 25mg; tabs.
Various generic manufacturers
Indications for Diethylpropion:
Short-term adjunct in management of exogenous obesity.
25mg 3 times daily 1 hr before meals and in midevening for night hunger or one 75mg sustained-release tab daily in midmorning.
Arteriosclerosis. Hypertension. Hyperthyroidism. Glaucoma. Agitation. Drug or alcohol abuse. During or within 14 days of MAOIs.
Discontinue after a few weeks as tolerance to anorectic effect occurs. Epilepsy. Cardiovascular disease. Arrhythmias. Diabetes. Prescribe limited supply to prevent overdose. Pregnancy (Cat.B). Nursing mothers.
Hypertensive crisis with MAOIs. Blocks guanethidine. Adverse reaction with alcohol. Arrhythmias may occur with general anesthetics. Antagonized by phenothiazines.
Abuse potential, impairment in hazardous activities, arrhythmias, hypertension, CNS overstimulation, psychosis, dry mouth, GI disturbances, urticaria, impotence, seizures, blood dyscrasias, dyspnea, hair loss, dysuria.
Formerly known under the brand names Tenuate, Tepanil (tabs); Tenuate Dospan, Tepanil Ten-tab (SR tabs).
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|